MISGAV, Israel--(BUSINESS WIRE)--The Trendlines Group announced it has completed the acquisition of intellectual property developed within the framework of an R&D agreement with Endo International plc. The agreement, which was signed in 2012, called for the co-development of novel medical devices and technologies in the areas of men’s health, women’s health and homecare with Ireland based Endo International plc. (Nasdaq:ENDP) (TSX: ENL).
Trendlines Labs, the technology development incubator of The Trendlines Group, developed cutting-edge medical technologies to meet unmet market needs identified by Endo. Under the acquisition agreement, Trendlines takes commercial responsibility for all intellectual property created in accordance with the parties’ agreement, while Endo benefits from revenues resulting from commercialization. The intellectual property concepts span a number of fields: pain management, urology, oncology, and pelvic health.
Yosi Hazan, CEO of Trendlines Labs, said, “Working closely with Endo, we developed technologies for prostate cancer diagnosis and trans-urethral prostatectomy that are now ready for commercialization. These technological solutions will make a real difference to those who suffer from prostate cancer and BPH.”
D. Todd Dollinger, Chairman and CEO of Trendlines, stated, “Our work with Endo furthers our market reach and is fundamental to our mission — creating and developing companies to improve the human condition.”
About Endo International plc
Endo International plc is a
global specialty healthcare company focused on improving patients’ lives
while creating shareholder value. Endo develops, manufactures, markets,
and distributes quality branded pharmaceutical, generic and device
products through its operating companies. Endo has global headquarters
in Dublin, Ireland and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.
About The Trendlines Group Ltd.
Trendlines creates and
develops companies in accordance with its mission to improve the human
condition. To that end, it discovers, invests in, and incubates medical
and agricultural technology companies, all of which are based in Israel.
Trendlines’ internal invention center, Trendlines Labs, creates new
technologies, either as principal or in collaboration with global
companies and partners to address unmet market needs.
